Status:
COMPLETED
INSIGHT - Post Marketing Surveillance
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Brief Summary
In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment ...
Eligibility Criteria
Inclusion
- In- and outpatients with diagnosis of hepatocellular carcinoma (HCC) and decision taken by the investigator to prescribe Nexavar
Exclusion
- Exclusion criteria must be read in conjunction with the local product information
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
791 Patients enrolled
Trial Details
Trial ID
NCT00792350
Start Date
April 1 2008
End Date
April 1 2014
Last Update
May 14 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Austria
2
Many Locations, Germany